Product Description
Mechanisms of Action: CYP17 Inhibitor,AR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocrin
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer|Bladder Cancer|Salivary Gland Cancer|Thyroid Cancer|Neck Pain|Head and Neck Cancer|Breast Cancer|Small Cell Sarcoma|Triple Negative Breast Cancer|Low Back Pain|Goodpasture Syndrome|Renal Cell Carcinoma|Small Cell Carcinoma|Melanoma|Glioblastoma|Basal Cell Carcinoma|Male Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 4CAST | P2 |
Recruiting |
Triple Negative Breast Cancer |
2026-07-01 |
|
| START | P2 |
Terminated |
Thyroid Cancer|Prostate Cancer|Neck Pain|Head and Neck Cancer|Goodpasture Syndrome|Low Back Pain|Small Cell Carcinoma|Renal Cell Carcinoma|Small Cell Sarcoma|Basal Cell Carcinoma|Glioblastoma|Salivary Gland Cancer|Bladder Cancer|Breast Cancer|Melanoma |
2021-02-28 |
|
| 2011-004103-20 | P2 |
Completed |
Prostate Cancer |
2019-01-23 |
|
| CLARITY-01 | P2 |
Completed |
Triple Negative Breast Cancer|Male Breast Cancer |
2019-01-01 |
50% |
| INO-VT-464-CL-001 | P2 |
Completed |
Prostate Cancer |
2018-12-01 |
12% |
| INO-VT-464-CL-003 | P2 |
Completed |
Prostate Cancer |
2018-12-01 |
50% |
| INO-VT-464-CL-004 | P2 |
Completed |
Prostate Cancer |
2017-12-01 |
12% |
| INO-VT-464-CL-002 | P2 |
Completed |
Triple Negative Breast Cancer|Prostate Cancer |
2017-09-01 |